greeksoup/ stock research

3D Systems Corp.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 9 March 2026: press release. Guidance figures: 2 new. The quarter’s numbers.

Key takeaways

  • Fourth-quarter revenue fell 4% year over year: Q4 revenue was $106.3 million, down 4% from $111.0 million a year earlier, and up 3% excluding Geomagic. Source
  • Adjusted EBITDA loss narrowed: Adjusted EBITDA loss was $5.3 million in Q4 versus $19.1 million, and $45.4 million for the year versus $66.4 million. Source
  • Personalized health services became largest healthcare unit: Personalized health services grew at double-digit rates in Q4 and for 2025, and is now the largest segment within healthcare. Source
  • Printer mix weighed on gross margin: Printer sales above expectations in the quarter weighed on gross margin; management expects consumables and services sales to follow as printers become operational. Source
  • Operating expense fell in Q4: Non-GAAP operating expense was $42.5 million in Q4 versus $58.4 million a year earlier, and $195.6 million for 2025 versus $250.3 million. Source
  • Remaining 2026 maturities total $3.9 million: $3.9 million of principal is scheduled to mature in Q4 2026, with $92.0 million due in 2030. Source
  • Q1 revenue range $91M to $94M: First-quarter 2026 revenue is expected between $91 million and $94 million, below the fourth quarter's $106.3 million, with Adjusted EBITDA between a $5 million and $3 million loss. Source

“We are pleased with our fourth quarter performance, which exceeded our expectations driven by both our Healthcare and Industrial segments.”

Dr. Jeffrey Graves, President and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Total revenue Sourcefirst quarter 2026$91 - $94 millionNew
Adjusted EBITDA Sourcefirst quarter 2026($5) million - ($3) millionNew
Aerospace and defense revenue Source202620% annual revenue growth

What changed from last quarter

  • New guidance: First-quarter 2026 revenue and Adjusted EBITDA ranges are new; the third-quarter release gave only a fourth-quarter growth range. Source
  • New: An equitization transaction retired most debt due in Q4 2026; scheduled maturities fell from $34.7 million at September 30 to $3.9 million. Source

Results and growth drivers

  • Fourth-quarter revenue fell 4% year over year: Q4 revenue was $106.3 million, down 4% from $111.0 million a year earlier, and up 3% excluding Geomagic. Source
  • Full-year revenue fell 12%: Full-year 2025 revenue was $386.9 million, down 12% from $440.1 million, or 7% lower excluding Geomagic. Source
  • Net income rose on disposition gains: Full-year net income attributable to the company was $29.9 million, or $0.19 diluted EPS, against a $255.6 million loss, and Q4 net loss was $19.5 million. Source
  • Adjusted EBITDA loss narrowed: Adjusted EBITDA loss was $5.3 million in Q4 versus $19.1 million, and $45.4 million for the year versus $66.4 million. Source

Segments and end markets

  • Healthcare revenue rose 25% in Q4: Healthcare Solutions was $50.5 million in the fourth quarter, up from $40.4 million; full-year healthcare revenue was $179.6 million, down 5%. Source
  • Industrial revenue fell 21% in Q4: Industrial Solutions was $55.8 million, down from $70.7 million and 11% lower excluding Geomagic; full-year industrial revenue was $207.3 million, down 17%. Source
  • Personalized health services became largest healthcare unit: Personalized health services grew at double-digit rates in Q4 and for 2025, and is now the largest segment within healthcare. Source
  • Trauma expansion driving healthcare growth: Management attributed the growth to expansion into the trauma market, with shorter cycle times for surgical planning and execution. Source
  • Dental grew on aligners and dentures: Dental grew at a double-digit sequential rate, helped by an aligner market recovery and a new denture manufacturing technology launch. Source

“We remain intensely focused on reducing overall spending, while prioritizing strategic investments that drive growth in our priority markets.”

Phyllis Nordstrom, Interim Chief Financial Officer

Products, services and printers

  • Products revenue down, services up: Products revenue was $62.6 million in Q4 versus $70.4 million, and $223.4 million for the year versus $279.2 million; services revenue was $43.7 million versus $40.6 million. Source
  • Printer and materials sales drove sequential growth: Management attributed the sequential increase in fourth-quarter revenue to printer and materials sales strengthening during the period. Source
  • Printer mix weighed on gross margin: Printer sales above expectations in the quarter weighed on gross margin; management expects consumables and services sales to follow as printers become operational. Source

Costs and margins

  • Operating expense fell in Q4: Non-GAAP operating expense was $42.5 million in Q4 versus $58.4 million a year earlier, and $195.6 million for 2025 versus $250.3 million. Source
  • Q4 gross margin little changed: GAAP gross margin was 30.8% against 31.0%; non-GAAP gross margin was 31.0% against 31.3% in the prior year period. Source
  • Margin rose excluding Geomagic: Excluding Geomagic, non-GAAP gross margin was 31.0% in Q4, up from 27.7% a year earlier. Source
  • Full-year margin fell excluding Geomagic: Full-year GAAP gross margin was 33.9% against 37.3%; excluding Geomagic, non-GAAP gross margin decreased by 70 basis points. Source

“2026 promises to be a year of continued growth based upon early feedback from dental labs across the US.”

Dr. Jeffrey Graves, President and CEO

Cash, debt and capital returns

  • Asset sale proceeds of $122.7 million: Proceeds from sale of assets and businesses, net of cash sold, were $122.7 million for 2025, reflecting the Geomagic divestiture. Source
  • Year-end cash of $97.1 million: Total cash at year-end was $97.1 million, including $95.6 million of cash and equivalents and $1.5 million of restricted cash. Source
  • Remaining 2026 maturities total $3.9 million: $3.9 million of principal is scheduled to mature in Q4 2026, with $92.0 million due in 2030. Source
  • Stock repurchases of $14.96 million: Stock repurchases were $14.96 million for 2025, and none were recorded in 2024. Source

Strategy and priority markets

  • New products focused on three markets: Management named med tech, dental, and aerospace and defense as markets of particular focus for new product development. Source
  • Titanium and PEEK printing valued by surgeons: Management said offering solutions printed in titanium or medical-grade PEEK is of significant value to surgeons treating patients. Source
  • Spending cuts alongside priority investments: Interim CFO Phyllis Nordstrom said management remains intensely focused on reducing overall spending while prioritizing strategic investments. Source

First-quarter 2026 guidance

  • Q1 revenue range $91M to $94M: First-quarter 2026 revenue is expected between $91 million and $94 million, below the fourth quarter's $106.3 million, with Adjusted EBITDA between a $5 million and $3 million loss. Source
  • Adjusted EBITDA not reconciled to GAAP: Management said it cannot reconcile forward-looking Adjusted EBITDA to GAAP without unreasonable effort, because legal, acquisition and restructuring items are hard to predict. Source
  • Results call held March 9: The company held a conference call and webcast on March 9, 2026 at 8:30 a.m. Eastern Time, with a replay available afterward. Source

Reporting basis and non-GAAP

  • Geomagic excluded from comparable growth: Geomagic was divested on April 1, 2025 for $119.4 million in cash; growth figures exclude it where periods are not comparable. Source
  • Non-GAAP excludes amortization and stock compensation: Non-GAAP measures exclude amortization of intangibles, acquisition costs, stock-based compensation, restructuring, impairment, and divestiture gains or losses. Source
  • Prior-year regenerative medicine one-time item: Q4 2024 included a one-time $8.7 million Regenerative Medicine accounting adjustment within Healthcare Solutions, noted for prior-year comparisons. Source

Coming up, as management said on 9 March 2026

  • Point-of-care centers expanding: Management said point-of-care centers are expanding to more leading research hospitals. Source
  • Continued top-line and bottom-line momentum: Management expects to continue its momentum in top-line growth and bottom-line performance through 2026. Source

Risks management discussed

  • Financial: Operating cash outflow was $87.8 million for 2025, against $44.9 million in 2024. Source
  • Demand: The prior release cited customers' extended curtailment of capital spending, while also reporting early improvement in key end markets.
  • External: The prior release listed tariff headwinds from rising printer sales as a factor in gross margin.

Earlier plans management reported on

  • Ahead: Management said fourth-quarter revenue exceeded the sequential growth range given in the third-quarter release. Source
  • Met: Management said the 15% full-year target was achieved, with aerospace and defense revenue up 16%. Source
  • On track: Management said the company is tracking well to its 20% growth expectation for 2026. Source
  • Met: Management said the programs delivered about $55 million of annualized cost savings in 2025. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.